Abstract
A 26-year-old man with limited-stage classic Hodgkin lymphoma (cHL) achieved complete response after standard treatment with combined modality treatment of involved-field radiation and four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy. Fourteen years later, enlarged mediastinal lymph nodes were revealed by computed tomography, and based on identical histological findings, he was diagnosed with cHL, considered to be a recurrence of the initial disease. HL is a rare subtype of malignant lymphoma in Japan, and there are limited data on well-documented cases in Japanese, especially very late recurrence. Our case has shown that CR could be achieved again with the use of brentuximab vedotin (BV) followed by autologous stem cell transplantation (ASCT) for such late recurrence. Although the possible risk factors for relapse of cHL remain uncertain, patients with late-relapse cHL that occurs 5 or more years after the end of initial therapy show better survival after additional treatment than that in patients with early-relapse cHL. Due to the possible occurrence of very late relapse, as described in the present case report, a reconsideration of strategies for long-term follow-up after chemoradiotherapy for limited-stage cHL is warranted.
Similar content being viewed by others
References
Brusamolino E, Baio A, Orlandi E et al (2006) Long-term events in adult patients with clinical stage IA-IIA nonbulky Hodgkin’s lymphoma treated with four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine and adjuvant radiotherapy: a single-institution 15-year follow-up. Clin Cancer Res 12:6487–6493
Bonadonna G, Bonfante V, Viviani S et al (2004) ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin’s disease: long-term results. J Clin Oncol 22:2835–2841
Shihabi S, Deutsch M, Jacobs SA (2001) Very late relapse of Hodgkin’s disease: a report of five patients. Am J Clin Oncol 24:576–578
Bröckelmann PJ, Goergen H, Kohnhorst C et al (2017) Late relapse of classical Hodgkin lymphoma: an analysis of the German Hodgkin Study Group HD7 to HD12 trials. J Clin Oncol 35:1444–1450
Pinczés L, Miltényi Z, Illés A (2018) Young adults diagnosed with Hodgkin lymphoma are at risk of relapsing late: a comprehensive analysis of late relapse in Hodgkin lymphoma. J Cancer Res Clin Oncol 144:935–9343
Markovic O, Andjelic B, Tarabar O et al (2017) Late relapse of Hodgkin’s lymphoma—is it different in clinical characteristics and outcome? J BUON 22:481–486
Provencio M, Salas C, Millán I et al (2010) Late relapses in Hodgkin lymphoma: a clinical and immunohistochemistry study. Leuk Lymphoma 51:1686–1691
Bodis S, Henry-Amar M, Bosq J et al (1993) Late relapse in early-stage Hodgkin’s disease patients enrolled on European Organization for Research and Treatment of Cancer protocols. J Clin Oncol 11:225–232
Armitage JO (2010) Early-stage Hodgkin’s lymphoma. N Engl J Med 363:653–662
Brousset P, Schlaifer D, Meggetto F et al (1994) Persistence of the same viral strain in early and late relapses of Epstein-Barr virus-associated Hodgkin’s disease. Blood 84:2447–2451
Siebert R, Fosså A, Kaiser W et al (1997) Recurrence of Hodgkin’s disease after 10 or more years: late relapse or de-novo malignancy due to HLA-DPB1*0301-linked susceptibility? Leuk Lymphoma 26:121–125
Meyer RM, Gospodarowicz MK, Connors JM et al (2012) ABVD alone versus radiation-based therapy in limited-stage Hodgkin’s lymphoma. N Engl J Med 366:399–408
Acknowledgements
We thank Editage (http://www.editage.jp) for English editing. No funding was received for this study.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflicts of interest.
Informed consent
The patient and his family provided consent for the publication of this case with the removal of all identifying information to maintain the patient’s anonymity and retain their privacy.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Nukui, J., Takahashi, H., Tokunaga, M. et al. Successful treatment with brentuximab vedotine for a patient with very late relapse of limited stage classic Hodgkin lymphoma. Int Canc Conf J 11, 27–30 (2022). https://doi.org/10.1007/s13691-021-00510-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13691-021-00510-1